Abstract
Purpose
To report 5-year survival in patients with primary parotid malignant tumours and assess the impact of various factors on survival or local control among diverse histologic groups.
Methods
A total of 65 patients with primary parotid malignant tumours who had surgery between 2003 and 2014 were identified. Demographic characteristics including age, T stage, N stage and clinical or pathological performance were analysed. According to risk stratification (based on pathology), 65 primary parotid malignant tumours were divided into high-risk (23, 35.38%) and low-risk (35, 53.85%) groups. Overall survival (OS) and disease-free survival (DFS) were recorded by the Kaplan–Meier methods.
Results
The 5-year overall survival rate for primary parotid malignant tumours was 70.9%. Patients older than 60 years with fixed mass, pain, facial-nerve palsy and high-grade N stage had adverse OS and DFS. Upon multivariable analysis, facial-nerve palsy (HR 24.59; 95% CI 2.338–178.446; P = 0.002) was the only independent predictive factor for OS. Patients with high-risk parotid malignant types were more likely to have tumour pain, facial-nerve palsy (Chi-square test: < 0.0001 and 0.02), lymphatic metastasis and local/regional recurrence (Chi-square test: 0.008 and 0.012).
Conclusions
Compared with low-risk parotid carcinoma, tumours with high-risk histological features tend to need aggressive surgical extirpation, neck dissection and postoperative radiotherapy.
Similar content being viewed by others
Abbreviations
- OS:
-
Overall survival
- DFS:
-
Disease-free survival
- WHO:
-
World Health Organization
- PPMT:
-
Primary parotid malignant tumour
- SPMT:
-
Secondary parotid malignant tumour
- HRs:
-
Hazard ratios
References
Lewis AG, Tong T, Maghami E (2016) Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin N Am 49(2):343–380. https://doi.org/10.1016/j.otc.2015.11.001
Nam SJ, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY (2016) Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol 23(13):4376–4383. https://doi.org/10.1245/s10434-016-5356-3
Lombardi D, McGurk M, Vander Poorten V, Guzzo M, Accorona R, Rampinelli V, Nicolai P (2017) Surgical treatment of salivary malignant tumors. Oral Oncol 65:102–113. https://doi.org/10.1016/j.oraloncology.2016.12.007
Liu Y, Su M, Yang Y, Zhao B, Qin L, Han Z (2017) Prognostic factors associated with decreased survival in patients with acinic cell carcinoma of the parotid gland. J Oral Maxillofac Surg 75(2):416–422. https://doi.org/10.1016/j.joms.2016.06.185
Bell RB, Dierks EJ, Homer L, Potter BE (2005) Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 63(7):917–928
Lima RA, Tavares MR, Dias FL, Kligerman J, Nascimento MF, Barbosa MM, Cernea CR, Soares JR, Santos IC, Salviano S (2005) Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 133(5):702–708. https://doi.org/10.1016/j.otohns.2005.08.001
Seethala RR (2009) An update on grading of salivary gland carcinomas. Head neck Pathol 3(1):69–77. https://doi.org/10.1007/s12105-009-0102-9
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474. https://doi.org/10.1245/s10434-010-0985-4
Rayess HM, Dezube A, Bawab I, Raza SN, Yoo GH, Lin HS, Jacobs JR (2017) Tumor differentiation as a prognostic factor for major salivary gland malignancies. Otolaryngol Head Neck Surg. https://doi.org/10.1177/0194599817700593
Walvekar RR, Filho PAA, Seethala RR, Gooding WE, Heron DE, Johnson JT, Ferris RL (2011) Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies. Head Neck 33(2):225–231
Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Loftus-Coll BM, Keus RB, van Leeuwen FE, Hart AA (1999) The development of a prognostic score for patients with parotid carcinoma. Cancer 85(9):2057–2067
Hocwald E, Korkmaz H, Yoo GH, Adsay V, Shibuya TY, Abrams J, Jacobs JR (2001) Prognostic factors in major salivary gland cancer. Laryngoscope 111(8):1434–1439. https://doi.org/10.1097/00005537-200108000-00021
Thielker J, Grosheva M, Ihrler S, Wittig A, Guntinas-Lichius O (2018) Contemporary management of benign and malignant parotid tumors. Front Surg 5:39. https://doi.org/10.3389/fsurg.2018.00039
Park GC, Roh JL, Cho KJ, Jung YG, Lee HW, Kim TG, Choi SH, Nam SY, Kim SY (2018) Survival outcome of intermediate-grade salivary gland carcinoma. Oncology 94(2):125–132. https://doi.org/10.1159/000484411
Son E, Panwar A, Mosher CH, Lydiatt D (2018) Cancers of the major salivary gland. J Oncol Pract 14(2):99–108. https://doi.org/10.1200/JOP.2017.026856
Ramirez-Perez F, Gonzalez-Garcia R, Hernandez-Vila C, Monje-Gil F, Ruiz-Laza L (2017) Is fine-needle aspiration a reliable tool in the diagnosis of malignant salivary gland tumors? J Cranio-Maxillo-fac Surg 45 (7):1074–1077. https://doi.org/10.1016/j.jcms.2017.03.019
Cracchiolo JR, Shaha AR (2016) Parotidectomy for parotid cancer. Otolaryngol Clin N Am 49(2):415–424. https://doi.org/10.1016/j.otc.2015.10.007
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest concerning the study.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of Eye & ENT Hospital of Fudan University and with the 1964 Helsinki Declaration and its later amendments.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Tao, L., Zhang, D., Zhang, M. et al. Clinical behaviours and prognoses of high- and low-risk parotid malignancies based on histology. Eur Arch Otorhinolaryngol 276, 497–503 (2019). https://doi.org/10.1007/s00405-018-5224-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-018-5224-9